Currently, RT-PCR is considered by most to be the “gold standard” for the detection of MRD in NPM1-mutant AML; thus, at our center, we have implemented RT-PCR, alongside other testing methods, to assess mutant NPM1 as a part of prospective testing used in real-time, during routine clinical practice. The gene discussed is NPM1; the disease is acute myeloid leukemia.